SpringWorks Therapeutics
Small molecule and biologic cancer therapeutics
- Sector
- Biotech
- Headquarters
- BALTIMORE, MD
- Founded
- 2017
- Latest Form D
- $12.8M, Sep 2017
- Total capital
- $12.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $12.8M
- 1 Form D · last Sep 2017
- 110 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 22 pending · first 2024
- Rank in peer group#40 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$12.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#40 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Carl GordonDirectorNamed in SEC Form D filings
- Carl L GordonDirectorNamed in SEC Form D filings
- Daniel S. LynchExecutive Officer, DirectorNamed in SEC Form D filings
- Daniel S. LynchExecutive Officer, DirectorNamed in SEC Form D filings
- Deval PatrickDirectorNamed in SEC Form D filings
- Freda Lewis-HallDirectorNamed in SEC Form D filings
Show all 14 people
- Freda Lewis-Hall, M.D.DirectorNamed in SEC Form D filings
- Jeffrey SchwartzDirectorNamed in SEC Form D filings
- Jeff SchwartzDirectorNamed in SEC Form D filings
- Lara Sullivan, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- Michael GrecoExecutive OfficerNamed in SEC Form D filings
- Peter KeenDirectorNamed in SEC Form D filings
- Saqib IslamExecutive Officer, DirectorNamed in SEC Form D filings
- Stephen SquintoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 18 granted of 40- PendingMirdametinib TreatmentUSPTOApplication 19670741
- GrantedImproved Treatment Of Ovarian Cancer With NirogacestatUSPTOUS 12,667,555
- GrantedCo-administration Of Mirdametinib And Lifirafenib For Use In Treating CancersUSPTOUS 12,667,560
Show all 40 patent records
- Mirdametinib TreatmentSep 17, 2026 · Application 19670741Pending
- Improved Treatment Of Ovarian Cancer With NirogacestatJun 30, 2026 · US 12,667,555Granted
- Co-administration Of Mirdametinib And Lifirafenib For Use In Treating CancersJun 30, 2026 · US 12,667,560Granted
- Mirdametinib TreatmentJun 23, 2026 · US 12,661,330Granted
- Chlorinated Tetralin Compounds And Pharmaceutical CompositionsApr 14, 2026 · US 12,599,587Granted
- Dosage Forms Of MirdametinibApr 2, 2026 · Application 19267096Pending
- Dispersible Formulations Of N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE And Uses ThereofMar 26, 2026 · Application 19234475Pending
- Combination Therapy With An Anti Bcma Antibody And A Gamma Secretase InhibitorMar 10, 2026 · US 12,570,752Granted
- Chlorinated Tetralin Compounds And Pharmaceutical CompositionsFeb 5, 2026 · Application 19351393Pending
- Treatment Of Multiple MyelomaJan 29, 2026 · Application 18993488Pending
- Treatment Of Ovarian Cancer With NirogacestatJan 1, 2026 · Application 19317994Pending
- Mirdametinib TreatmentDec 25, 2025 · Application 19237417Pending
- Mirdametinib TreatmentDec 25, 2025 · Application 19237400Pending
- Mirdametinib TreatmentDec 25, 2025 · Application 18912341Pending
- Mirdametinib TreatmentDec 25, 2025 · Application 18912367Pending
- Mirdametinib TreatmentDec 25, 2025 · Application 18912278Pending
- Mirdametinib TreatmentDec 25, 2025 · Application 19237465Pending
- Mirdametinib TreatmentDec 25, 2025 · Application 18912328Pending
- Mirdametinib TreatmentDec 25, 2025 · Application 19237500Pending
- Synthesis Of NirogacestatNov 27, 2025 · Application 19061962Pending
- Treatment Of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (pn) In Pediatric Patients With MirdametinibSep 4, 2025 · Application 19082462Pending
- Crystalline Solids Of Mek Inhibitor N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE And Uses ThereofAug 28, 2025 · Application 19039603Pending
- Non-linear Dosing Of MirdametinibAug 28, 2025 · Application 19053783Pending
- Mirdametinib TreatmentAug 19, 2025 · US 12,390,430Granted
- Dosage Forms Of MirdametinibAug 12, 2025 · US 12,383,517Granted
- Fluorinated Phenylamino Compounds And Pharmaceutical CompositionsJul 17, 2025 · Application 18841924Pending
- Dispersible Formulations Of N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE And Uses ThereofJul 15, 2025 · US 12,357,597Granted
- Mirdametinib TreatmentJun 10, 2025 · US 12,324,791Granted
- Treatment of cutaneous neurofibromas with MirdametinibMay 29, 2025 · Application 18841882Pending
- Treatment Of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (pn) In Pediatric Patients With MirdametinibMay 13, 2025 · US 12,295,925Granted
- Crystalline Solids Of Mek Inhibitor N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE And Uses ThereofApr 15, 2025 · US 12,275,688Granted
- Non-linear Dosing Of MirdametinibApr 1, 2025 · US 12,263,146Granted
- Mirdametinib TreatmentMar 25, 2025 · US 12,257,215Granted
- Synthesis Of NirogacestatMar 11, 2025 · US 12,247,012Granted
- Synthesis Of NirogacestatFeb 25, 2025 · US 12,234,210Granted
- Mirdametinib TreatmentFeb 11, 2025 · US 12,220,390Granted
- Treatments With NirogacestatJan 23, 2025 · Application 18908159Pending
- Treatments With NirogacestatJan 7, 2025 · US 12,186,305Granted
- Treatments With NirogacestatNov 12, 2024 · US 12,138,246Granted
- Covalent Egfr Inhibitors And Methods Of Use ThereofOct 24, 2024 · Application 18701077Pending
Related companies, and why
- Hoth Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Cristcot LLCSimilar federal contract value in Biotech · null in contracts
- Angiex, Inc.Similar federal contract value in Biotech · null in contracts
- ALAMAB THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- Alkahest, Inc.Similar federal contract value in Biotech · null in contracts
- Evercrisp Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .